Clinical Trial Update: Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Mepolizumab is being studied as a steroid-sparing treatment option for eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) in Phase 1/2 trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Churg Strauss Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-03-22